Intervention not reported
Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
CIN2+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention leads to lower CIN2+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
CIN3+ associated with HPV16/18 (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention leads to lower CIN3+ associated with HPV16/18 (age 15 to 26 years) (high certainty).
1 finding from 1 review
Intervention not reported
AIS associated with HPV16/18 or 6/11/16/18 (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention probably leads to lower AIS associated with HPV16/18 or 6/11/16/18 (age 15 to 26 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The intervention leads to lower any CIN2+ irrespective of HPV type (age 15 to 26 years) (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Any AIS irrespective of HPV type ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
CIN2+ associated with HPV16/18. · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower CIN2+ associated with HPV16/18. (high certainty).
1 finding from 1 review
Intervention not reported
CIN3+ associated with HPV16/18 · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower CIN3+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
AIS associated with HPV16/18 · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention probably leads to lower AIS associated with HPV16/18 (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower any CIN2+ irrespective of HPV type, bivalent or quadrivalent vaccine (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN2+ irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower any CIN2+ irrespective of HPV type (high certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type, bivalent or quadrivalent vaccine · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention showed no clear difference in any CIN3+ irrespective of HPV type, bivalent or quadrivalent vaccine (moderate certainty).
1 finding from 1 review
Intervention not reported
Any CIN3+ irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention leads to lower any CIN3+ irrespective of HPV type (high certainty).
1 finding from 1 review
Intervention not reported
Any AIS irrespective of HPV type · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination
The intervention probably leads to lower any AIS irrespective of HPV type (moderate certainty).
1 finding from 1 review
Intervention not reported
Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
CIN2+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower CIN2+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
CIN3+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower CIN3+ associated with HPV16/18 (high certainty).
1 finding from 1 review
Intervention not reported
Adeno carcinoma in situ (AIS) associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline
The intervention leads to lower adeno carcinoma in situ (AIS) associated with HPV16/18 (high certainty).
1 finding from 1 review